Literature DB >> 12351959

Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.

Luisa Valer1, Carmen De Mendoza, Daniel González De Requena, Pablo Labarga, Adolfo García-Henarejos, Pablo Barreiro, Francisca Guerrero, Antonio Vergara, Vincent Soriano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12351959     DOI： 10.1097/00002030-200209270-00016

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  8 in total

1.  Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.

Authors:  Ana Marin-Niebla; Luis Fernando Lopez-Cortes; Rosa Ruiz-Valderas; Pompeyo Viciana; Rosario Mata; Alicia Gutierrez; Rosario Pascual; Magdalena Rodriguez
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

Review 2.  Practical guidelines to interpret plasma concentrations of antiretroviral drugs.

Authors:  Bregt S Kappelhoff; Kristel M L Crommentuyn; Monique M R de Maat; Jan W Mulder; Alwin D R Huitema; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 3.  Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

Authors:  Rob E Aarnoutse; Jonathan M Schapiro; Charles A B Boucher; Yechiel A Hekster; David M Burger
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Saquinavir: a review of its use in boosted regimens for treating HIV infection.

Authors:  Greg L Plosker; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.

Authors:  Laura Dickinson; Marta Boffito; David J Back; Saye H Khoo; Anton L Pozniak; Peter Mugyenyi; Concepta Merry; Reshma Saskia Autar; David M Burger; Leon J Aarons
Journal:  J Antimicrob Chemother       Date:  2008-09-29       Impact factor: 5.790

Review 6.  Tipranavir.

Authors:  Greg L Plosker; David P Figgitt
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing.

Authors:  Laura Dickinson; Marta Boffito; Saye H Khoo; Malte Schutz; Leon J Aarons; Anton L Pozniak; David J Back
Journal:  J Antimicrob Chemother       Date:  2008-05-07       Impact factor: 5.790

8.  Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients.

Authors:  C Stephan; H Jaeger; A Carganico; G Knecht; T Lutz; C Mayr; F A Mosthaf; S Koeppe; M Mueller; E Wolf; A Tappe; E Wellmann; H Knechten
Journal:  Eur J Med Res       Date:  2010-09-24       Impact factor: 2.175
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.